Thursday, January 16, 2014
Immune checkpoint proteins are among the hottest targets in
the cancer immunotherapy space, but many patients do not respond to individual
antibodies against the targets. A team of U.S. researchers has found that
combining a cocktail of antibodies targeting checkpoint proteins with
peptide-based cancer vaccines induced a potent and tumor-specific
T cell response to treat melanoma.1
L. SciBX 7(2);
Published online Jan. 16, 2013
1. Fourcade, J. et al.
Cancer Res.; published online Dec. 16, 2013;
Contact: Hassane M. Zarour, University of Pittsburgh School of Medicine,
2. Duraiswamy, J. et
al. Cancer Res. 73, 3591-3603 (2013)
AND INSTITUTIONS MENTIONED
AnaptysBio Inc., San Diego, Calif.
Brigham and Women's Hospital, Boston, Mass.
Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.
CoStim Pharmaceuticals Inc., Boston, Mass.
CureTech Ltd., Yavne, Israel
Harvard Medical School, Boston, Mass.
Ono Pharmaceutical Co. Ltd. (Tokyo:4528),
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif.
University of Lausanne, Lausanne, Switzerland
University of Maryland School of Medicine, Baltimore, Md.
The University of North Carolina at Chapel Hill, Chapel Hill, N.C.
University of Pennsylvania, Philadelphia, Pa.
University of Pittsburgh School of Medicine, Pittsburgh, Pa.